NCT00645307 – A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With an Open-Label Extension Evaluating Extended Release OROS® Paliperidone in the Prevention of Recurrence in Subjects With Schizophrenia – Open Label Phase Posted on July 18, 2016 by tsuperadmin -
An open-label, long-term study of risperidone for the treatment of behavioral disturbances in patients with dementia Posted on May 9, 2016 by tsuperadmin -
NCT00105326 – A Double-blind, Placebo-controlled, Randomized Study Evaluating the Effect of Paliperidone ER Compared With Placebo on Sleep Architecture in Subjects With Schizophrenia Posted on March 31, 2016 by tsuperadmin -
NCT00524043 – A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of a Fixed Dosage of 1.5 mg/Day of Paliperidone Extended Release (ER) in the Treatment of Subjects With Schizophrenia Posted on March 31, 2016 by tsuperadmin -
NCT00490971 – A Randomized, Double-Blind, Active- and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Extended-Release Paliperidone as Maintenance Treatment After an Acute Manic or Mixed Episode Associated With Bipolar I Disorder Posted on March 31, 2016 by tsuperadmin -
NCT01662310 – Paliperidone Extended Release Tablets for the Prevention of Relapse in Subjects With Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Posted on March 31, 2016 by tsuperadmin -
NCT01193153 – A Randomized, Double-Blind, Placebo-Controlled, Parellel-Group Study of Paliperidone Palmitate Evaluating Time to Relapse in Subjects With Schizoaffective Disorder Posted on March 31, 2016 by tsuperadmin -
NCT01529515 – A Randomized, Multicenter, Double-Blind, Relapse Prevention Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Subjects With Schizophrenia Posted on March 31, 2016 by tsuperadmin -
The safety and efficacy of risperidone 8 mg qd and 4 mg qd compared to placebo in the treatment of schizophrenia Posted on March 31, 2016 by tsuperadmin -
NCT00253123 – A Randomized, Double-Blind, Placebo-Controlled Study of Risperidone for Treatment of Behavioral Disturbances in Subjects With Dementia Posted on March 31, 2016 by tsuperadmin -